Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Patent metadata

Field	Value
Publication number	US-9956166-B2
Application number	US-201414484235-A
Country	US
Kind code	B2
Filing date	Sep 11, 2014
Priority date	Sep 18, 2013
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.

First claim

We claim:

1. A method for preventing or reducing physiological changes associated with myocardial infarction, comprising administering an effective amount of resiniferatoxin (RTX) directly to a tissue site of a post-myocardial infarction patient, the tissue site selected from the group consisting of epicardium, dorsal root ganglion and the subarachnoid space of the T1-T4 region of the spinal column, and attenuating cardiac sympathetic afferent reflex (CSAR) in the post-myocardial infarction patient for a period of at least 4 weeks after administration; and
wherein the physiological changes associated with myocardial infarction are selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end-diastolic pressure (LVEDP), lung edema, and combinations thereof.

2. The method for preventing or reducing physiological changes associated with myocardial infarction of claim 1 , wherein the concentration of RTX administered is from about 100 ng/ml to about 500 μg/ml.

3. The method for preventing or reducing physiological changes associated with myocardial infarction of claim 1 , wherein the concentration of RTX administered is from about 5 μg/ml to about 80 μg/ml.

4. The method for preventing or reducing physiological changes associated with myocardial infarction of claim 1 , wherein the concentration of RTX administered is from about 20 μg/ml to about 60 μg/ml.

5. The method for preventing or reducing physiological changes associated with myocardial infarction of claim 1 , wherein, in a human, the administration of RTX is accomplished by a technique selected from the group consisting of pericardiocentesis, catheter based administration into the coronary artery circulation, intrathecal administration to a T1-T4 location and intraganglionic administration to a T1-T4 ganglion.

6. The method for preventing or reducing physiological changes associated with myocardial infarction of claim 1 , wherein the period is at least 9 weeks.

Assignees

• Zucker Irving H
• Wang Hanjun
• Sorrento Therapeutics Inc

Inventors

• Zucker Irving H
• Wang Hanjun

Classifications

• A61K9/0085

  Brain, e.g. brain implants; Spinal cord · CPC title

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/357

  having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title